ZA200900316B - Antagonists of endothelial differentiation gene subfamily 3 (EDG-3, S1P3) receptors for prevention and treatment of ocular disorders - Google Patents

Antagonists of endothelial differentiation gene subfamily 3 (EDG-3, S1P3) receptors for prevention and treatment of ocular disorders

Info

Publication number
ZA200900316B
ZA200900316B ZA200900316A ZA200900316A ZA200900316B ZA 200900316 B ZA200900316 B ZA 200900316B ZA 200900316 A ZA200900316 A ZA 200900316A ZA 200900316 A ZA200900316 A ZA 200900316A ZA 200900316 B ZA200900316 B ZA 200900316B
Authority
ZA
South Africa
Prior art keywords
edg
antagonists
receptors
prevention
treatment
Prior art date
Application number
ZA200900316A
Other languages
English (en)
Inventor
Debra L Fleenor
Allan R Shepard
Lok-Hou Pang
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of ZA200900316B publication Critical patent/ZA200900316B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200900316A 2006-07-25 2007-07-25 Antagonists of endothelial differentiation gene subfamily 3 (EDG-3, S1P3) receptors for prevention and treatment of ocular disorders ZA200900316B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83308006P 2006-07-25 2006-07-25

Publications (1)

Publication Number Publication Date
ZA200900316B true ZA200900316B (en) 2010-05-26

Family

ID=38982306

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200900316A ZA200900316B (en) 2006-07-25 2007-07-25 Antagonists of endothelial differentiation gene subfamily 3 (EDG-3, S1P3) receptors for prevention and treatment of ocular disorders

Country Status (11)

Country Link
US (2) US20080025973A1 (es)
EP (1) EP2068856A2 (es)
JP (1) JP2009544734A (es)
KR (1) KR20090033886A (es)
CN (1) CN101505744A (es)
AU (1) AU2007279311A1 (es)
BR (1) BRPI0714593A2 (es)
CA (1) CA2657480A1 (es)
MX (1) MX2009000907A (es)
WO (1) WO2008014338A2 (es)
ZA (1) ZA200900316B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0513110A (pt) * 2004-07-16 2008-04-29 Kyorin Seiyaku Kk medicamento compreendendo composto sulfeto diaril ou composto éter diaril tendo uma estrutura 2-amina-1, 3-propanediol tendo uma atividade de redução de linfócitos perifericamente circulante, em combinação com um agente imunosupressivo e/ou um agente antiinflamatório e método de expressão de prevenção do efeito secundário
CA2583846C (en) 2004-10-12 2013-10-01 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride or hydrates thereof, and intermediates in the production thereof
CA2624909C (en) * 2005-10-07 2013-10-01 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for treating liver disease containing 2-amino-1,3-propanediol derivative as active ingredient, and method for treating liver disease
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ574012A (en) * 2006-08-08 2012-02-24 Kyorin Seiyaku Kk Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
KR101339976B1 (ko) * 2006-08-08 2013-12-10 교린 세이야꾸 가부시키 가이샤 아미노인산에스테르 유도체 및 그들을 유효성분으로 하는 ｓ1ｐ 수용체 조절제
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
EP2262497A2 (en) * 2008-03-17 2010-12-22 Allergan, Inc. S1p3 receptor inhibitors for treating inflammation
WO2010129553A1 (en) * 2009-05-05 2010-11-11 Allergan, Inc. S1p3 receptor inhibitors for treating conditions of the eye
US20110039900A1 (en) * 2009-08-11 2011-02-17 Allergan, Inc. Isothiozoles for treating conditions of the eye
KR20120081109A (ko) * 2009-09-30 2012-07-18 스티펠 리서치 오스트레일리아 피티와이 리미티드 미용 폼
CN102146411B (zh) * 2011-01-06 2013-01-02 中国人民解放军第三军医大学第三附属医院 新型双功能抗瘢痕和组织纤维化寡聚核苷酸药物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013811A1 (de) * 1993-11-17 1995-05-26 Byk Nederland Bv Verwendung substituierter thiazolidinderivate zur behandlung von erhöhtem augeninnendruck
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5750652A (en) * 1994-01-21 1998-05-12 Yale University Deltex proteins
ATE362770T1 (de) * 2000-02-09 2007-06-15 Bas Medical Inc Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
JP2001261575A (ja) * 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
JP2002332278A (ja) * 2001-05-08 2002-11-22 Human Science Shinko Zaidan Ｅｄｇ受容体拮抗作用を有する複素環誘導体
KR20040104566A (ko) * 2002-04-30 2004-12-10 알콘, 인코퍼레이티드 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ｃｔｇｆ)의활성 및/또는 발현 조절, 저해, 또는 변조제
EP1546110A4 (en) * 2002-07-30 2008-03-26 Univ Virginia ACTIVE COMPOUNDS IN THE SIGNALING OF SPHINGOSINE 1-PHOSPHATE
CA2495917A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
FR2845003A1 (fr) * 2002-09-30 2004-04-02 Merck Sante Sas Utilisation de derives de thiazolidinedione comme inhibiteurs de l'aldose reductase
CA2532064A1 (en) * 2003-07-15 2005-02-03 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
JP2005247691A (ja) * 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬
WO2006063033A2 (en) * 2004-12-06 2006-06-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
US8546452B2 (en) * 2005-10-12 2013-10-01 Toa Eiyo Ltd. S1P3 receptor antagonist
CN101460458A (zh) * 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物

Also Published As

Publication number Publication date
JP2009544734A (ja) 2009-12-17
US20080025973A1 (en) 2008-01-31
WO2008014338A3 (en) 2008-12-24
BRPI0714593A2 (pt) 2013-05-07
WO2008014338A2 (en) 2008-01-31
CN101505744A (zh) 2009-08-12
CA2657480A1 (en) 2008-01-31
US20100183629A1 (en) 2010-07-22
EP2068856A2 (en) 2009-06-17
AU2007279311A1 (en) 2008-01-31
KR20090033886A (ko) 2009-04-06
MX2009000907A (es) 2009-02-04

Similar Documents

Publication Publication Date Title
ZA200900316B (en) Antagonists of endothelial differentiation gene subfamily 3 (EDG-3, S1P3) receptors for prevention and treatment of ocular disorders
IL186598A0 (en) Composition and method for the treatment or prevention of glaucoma and ocular hypertension
PL2019683T5 (pl) Podawanie czynników wzrostu do leczenia zaburzeń OUN
HK1166983A1 (zh) 包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
EP1893216A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
WO2008029276A8 (en) Compositions and methods for the treatment of ophthalmic disease
IL191283A (en) Compositions for treating eye irregularities
WO2007003411A3 (en) Kinin antagonists for treating bladder dysfunction
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
EP2041067A4 (en) ANTAGONISTS OF CXCR4 COMPRISING DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL DISORDERS
WO2006023460A3 (en) COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
EP1881823A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF EYE DISEASES
IL180108A0 (en) Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders
PT2374472T (pt) Composições e métodos para o tratamento de afeções oftalmológicas
PL2418201T3 (pl) Polimorficzne postaci p-hydroksybeznoesanu (2S)-(4E)-N-metylo-5-[3-(5-izopropoksypirydyn)ylo]-4-penteno-2-aminy do leczenia zaburzeń ośrodkowego układu nerwowego
IL198005A0 (en) Ccr2 antagonists for treatment of fibrosis
IL187966A0 (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
WO2007141284A3 (en) Treatment of gastrointestinal disorders with cgrp antagonists
WO2007146349A3 (en) Cgrp receptor antagonists
EP2056840A4 (en) COMPOSITIONS, DEVICES AND METHODS OF TREATING MORBUS HUNTINGTON BY INTRA-CRANICAL LEVY FROM SIRNA
EP1899318A4 (en) NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF STOMACH DARM DISEASES
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
EP2064347A4 (en) METHODS FOR THE IDENTIFICATION, EVALUATION AND TREATMENT OF PATIENTS WITH DC CHIMIOKINE RECEPTOR 2 (CCR-2) MEDIATION DISORDERS
ZA200904281B (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders